Haploidentical family member transplants for patients with chronic myeloid leukaemia: a report of the Chronic Leukaemia Working Party of off European Group for Blood and Marrow Transplantation (EBMT)
Details
Serval ID
serval:BIB_DDC6803C30C7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Haploidentical family member transplants for patients with chronic myeloid leukaemia: a report of the Chronic Leukaemia Working Party of off European Group for Blood and Marrow Transplantation (EBMT)
Journal
Bone Marrow Transplantation
ISSN
0268-3369 (Print)
Publication state
Published
Issued date
06/1997
Volume
19
Number
12
Pages
1197-203
Notes
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Jun
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Jun
Abstract
Within the registry of the chronic leukaemia working party of the European Group for Blood and Marrow Transplantation, data were available from 103 patients with chronic myeloid leukaemia who were treated by bone marrow transplantation from haploidentical family members. The patients of median age 30 years were transplanted between 1983 and 1994 in 25 European centres. The overall probabilities of survival and leukaemia-free survival (LFS) at 5 years were 32 and 25%, respectively. In univariate analysis, two factors were identified which affected survival and LFS, ie the state of disease at the time of transplant and the degree of HLA disparity. Fifty-nine patients were transplanted in first chronic phase and the probability of survival at 2 years was 47%. Forty-four patients received their transplants for advanced disease and their probability of survival at 2 years was 25% (P = 0.004). Donor bone marrow was HLA-mismatched for 0-1 antigens in 54 patients (group 1) and for 2-3 antigens in 49 patients (group 2). At 2 years, the probabilities of survival for groups 1 and 2 were 46 and 27% (P < 0.02) and the probabilities of LFS were 43 and 24% (P < 0.03), respectively. Multivariate analysis confirmed the prognostic importance of the disease stage and of the HLA disparity. Patients transplanted in first chronic phase from a donor mismatched for 0-1 HLA antigens had a probability of survival of 52% at 2 years compared with 19% for patients transplanted in advanced disease stage from donors mismatched for 2-3 HLA antigens.
Keywords
Adolescent
Adult
Aged
*Bone Marrow Transplantation/adverse effects/immunology/mortality
Child
Child, Preschool
Europe
Family
Female
Graft Survival
Graft vs Host Disease/etiology
HLA Antigens
Haplotypes
Humans
Infant
Leukemia, Myeloid, Chronic/immunology/mortality/*therapy
Living Donors
Male
Middle Aged
Multivariate Analysis
Prognosis
Recurrence
Registries
Retrospective Studies
Risk Factors
Survival Rate
Transplantation, Homologous
Pubmed
Web of science
Open Access
Yes
Create date
28/01/2008 12:33
Last modification date
20/08/2019 17:02